Valuation: Ocugen, Inc.

Market Cap 484M 423M 391M 361M 680M 46.5B 693M 4.66B 1.83B 22.77B 1.82B 1.78B 78.4B P/E 2026 *
-6.34x
P/E 2027 * -5.91x
Enterprise Value 422M 368M 341M 315M 593M 40.49B 603M 4.06B 1.59B 19.83B 1.58B 1.55B 68.28B EV / Sales 2026 *
96.5x
EV / Sales 2027 * 43.9x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day+1.42%
1 week-4.67%
Current month-6.54%
1 month+18.18%
3 months-20.56%
6 months-23.94%
Current year+5.93%
1 week 1.38
Extreme 1.38
1.5
1 month 1.16
Extreme 1.16
1.69
Current year 1.16
Extreme 1.16
2.72
1 year 0.93
Extreme 0.931
2.72
3 years 0.34
Extreme 0.345
2.72
5 years 0.34
Extreme 0.345
17.65
10 years 0.17
Extreme 0.17
18.77
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Operating Officer - 01/03/2026
Director TitleAgeSince
Chairman 62 27/09/2019
Director/Board Member 59 01/09/2013
Director/Board Member 59 01/09/2019
Date Insider Type Main position Quantity % Market Cap.
06-15Buy

Chief Financial Officer

21,000 0.0062%
06-11Free

Director

170,100 0.0502%
06-11Free

Founder

170,100 0.0502%
Change 5-day change 1-year change 3-year change Capi.($)
+1.42%-4.67%+28.83%+144.99% 484M
-0.46%+1.33%+3.02%+7.28% 50.35B
+0.55%-2.88%+382.07%+593.81% 39.32B
+0.13%-0.19%+29.79%-6.00% 34.69B
+0.86%-0.78%+21.58%+56.15% 34.08B
-1.31%-3.03%+2.51%+25.24% 26.63B
+0.13%-0.52% - - 16.49B
+1.13%-1.85%+67.36%+120.46% 15.31B
+0.23%+3.13%+14.73%+17.74% 13.8B
+1.13%-0.44%+12.34%-31.79% 12.87B
Average +0.38%-1.21%+62.47%+103.10% 24.4B
Weighted average by Cap. +0.14%-0.74%+80.95%+122.38%

Financials

2026 *2027 *
Net sales 4.37M 3.82M 3.53M 3.26M 6.14M 419M 6.25M 42.07M 16.51M 205M 16.4M 16.04M 707M 11.02M 9.63M 8.9M 8.22M 15.49M 1.06B 15.77M 106M 41.65M 518M 41.39M 40.47M 1.78B
Net income -76.84M -67.15M -62.08M -57.35M -108M -7.38B -110M -740M -290M -3.61B -289M -282M -12.45B -85.3M -74.54M -68.91M -63.66M -120M -8.19B -122M -822M -322M -4.01B -320M -313M -13.81B
Net Debt -62.5M -54.62M -50.49M -46.65M -87.85M -6B -89.44M -602M -236M -2.94B -235M -230M -10.12B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
116
Date Price Change Volume
14/07/26 $1.430 +1.42% 4,964,447
13/07/26 $1.410 -4.08% 5,548,395
10/07/26 $1.470 0.00% 3,513,278
09/07/26 $1.470 -2.00% 5,465,970
08/07/26 $1.500 0.00% 7,570,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.430USD
Average target price
11.43USD
Spread / Average Target
+699.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCGN Stock